Key result
Irbesartan pretreatment significantly reduced myocardial inflammatory cytokines, chemokines, apoptosis, and plasma cardiac troponin I, ameliorating ischemia/reperfusion injury in rats.
Why the study?
Myocardial ischemia-reperfusion represents a clinically relevant problem associated with revascularization, prompting investigation into whether irbesartan can ameliorate myocardial ischemia-reperfusion injury.
Does Irbesartan reduce myocardial injury, inflammation, and apoptosis in a rat model of myocardial ischemia/reperfusion?
Does Irbesartan reduce myocardial injury, inflammation, and apoptosis in a rat model of myocardial ischemia/reperfusion?
Irbesartan pretreatment ameliorates myocardial ischemia/reperfusion injury in rats by reducing inflammatory responses and apoptosis.
Answers are grounded in this paper and cite their sources.
Irbesartan may attenuate rat myocardial I/R injury; leaves open translation to human ischemia-reperfusion.
Myocardial ischemia–reperfusion (I-R) represents a clinically relevant problem associated with thrombolysis, angioplasty and coronary bypass surgery. This study was undertaken to investigate the potential role of Irbesartan in amelioration of myocardial I/R injury induced by ligation of coronary artery (LAD) in a rat model. We are pretreated the animals with Irbesartan 3mg/kg i.p. 30 minutes before ligation of LAD. At the end of experiment (2 h of reperfusion), blood samples were collected from the heart for measurement of plasma level of cardiac troponin I (cTn-I). Compared with the sham group, levels of myocardial TNF-α, IL-1β, IL-6, MCP-1, MIP-1 alpha, and plasma cTn-I were increased (P<0.05). Histologically, all rats in control group showed significant cardiac injury after I-R. Furthermore, rats in control group showed significant apoptosis. Irbesartan significantly counteract the increased in myocardium level of TNF-α, IL-1B, IL-6, MCP-1, MIP-1 alpha, plasma cTn-I and apoptotosis (P<0.05). Histological analysis revealed that Irbesartan markedly reduced the severity of heart injury in the rats underwent LAD ligation procedure. We concluded that Irbesartan may ameliorate myocardial I/R injury in rats via interfering with inflammatory reactions and apoptosis which induced by I/R injury.
No takes yet. Share an insight, caveat, or question.
Hadi et al. (2019) studied Myocardial ischemia/reperfusion injury (n=40). Irbesartan vs. Normal saline (vehicle) and sham was evaluated on Myocardial levels of inflammatory cytokines, chemokines, apoptosis, and plasma cTn-I (p=<0.05). Irbesartan pretreatment significantly reduced myocardial inflammatory cytokines, chemokines, apoptosis, and plasma cardiac troponin I, ameliorating ischemia/reperfusion injury in rats.
Synapse has enriched 10 related papers. Consider them for comparative context: